HC Wainwright Reaffirms Buy Rating for InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 258.74% from the company’s previous close.

InflaRx Trading Up 4.7 %

IFRX stock traded up $0.10 during mid-day trading on Friday, hitting $2.23. The stock had a trading volume of 22,827 shares, compared to its average volume of 187,848. The firm has a fifty day simple moving average of $1.92 and a 200 day simple moving average of $1.67. InflaRx has a 52 week low of $1.16 and a 52 week high of $2.82. The firm has a market capitalization of $131.31 million, a P/E ratio of -2.06 and a beta of 1.67.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.